GB002 (seralutinib) ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 86 | Pulmonary arterial hypertension | 2 |
86. Pulmonary arterial hypertension
Clinical trials : 1,181 / Drugs : 701 - (DrugBank : 126) / Drug target genes : 105 - Drug target pathways : 192
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04816604 (ClinicalTrials.gov) | April 5, 2021 | 23/3/2021 | Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) | An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension | Drug: GB002 (seralutinib);Device: Generic Dry Powder Inhaler | GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | NULL | Recruiting | 18 Years | 80 Years | All | 100 | Phase 2 | United States;France;Germany;Spain |
| 2 | NCT04456998 (ClinicalTrials.gov) | December 14, 2020 | 30/6/2020 | GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH) | Pulmonary Artery Hypertension | Drug: GB002 (seralutinib);Drug: Placebo;Device: Generic Dry Powder Inhaler | GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | NULL | Recruiting | 18 Years | 75 Years | All | 80 | Phase 2 | United States;Australia;Austria;Belgium;Canada;Czechia;France;Germany;Israel;Serbia;Spain;United Kingdom |